Effect of Steroid Therapy on Growth hormone in Children with Nephrotic Syndrome | ||||
| Benha Journal of Applied Sciences | ||||
| Article 13, Volume 6, Issue 4, August 2021, Page 79-87 PDF (537.57 K) | ||||
| Document Type: Original Research Papers | ||||
| DOI: 10.21608/bjas.2021.189537 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| A.A. Abd El-hameed1; S.A. El-Gendy1; E.R. Abd El-gawaad2; R.A. Elsayed1; H.H. Mahmoud1 | ||||
| 1pediatrics, Dept., Faculty of Medicine, Benha Univ., Benha, Egypt | ||||
| 2clinical and chemical pathology, Dept., Faculty of Medicine, Benha Univ., Benha, Egypt | ||||
| Abstract | ||||
| Background: Nephrotic syndrome is the most frequent kidney-related condition in the United States today, providing a severe health risk. The cornerstone of therapy is still corticosteroids. Protein deficiency was a major cause of linear growth retardation in nephrotic individuals before steroids were administered. The goal of our research was to see how corticosteroids affected growth hormone in children with nephrotic syndrome. Methodologies: From February to December 2020, a cross-sectional research was conducted on children with nephrotic syndrome who visited the Benha University Nephrology clinic. After receiving written agreement from the patients' parents, the research included 36 patients with nephritic syndrome of both sexes, divided into two groups: corticosteroid response group and corticosteroid plus other immunosuppressive medications group. The following conditions were applied to all of the instances in the study: Growth hormone level in blood was measured after a thorough history, full clinical examination, and laboratory testing. Results: The majority of our NS patients (66.7%) were on corticosteroid medication, while 33.3 percent were on corticosteroid plus immunosuppressive medication, according to our research. Complete remission was 1 (2.8%), steroid dependent was 20 (55.5%), rare recurrence was 3 (8.4%), and corticosteroid resistant was 12 in our research (33.3). According to the findings of the present research, small stature accounted for 15 percent of the cases analysed (41.7 percent ). The G.H distribution in the examined cases was found to vary between 0.04 and 2.80ng/ml, with a mean of 0.76 0.86. The distribution of elicited growth hormone in the examined patients varied from 1.17 to 14.60 (ng/ml), with a mean of 5.28 2.81. According to this research, the distribution of activated growth hormone categories among the analysed patients was as follows: borderline (10.78%), normal (6.17%), and subnormal (20%). (55.6 percent ). There was a statistically significant negative connection between cumulative steroid dosage and mortality in the present trial (growth hormone and provocated Growth hormone). Conclusion: The majority of children with nephrotic syndrome exhibited a height disadvantage. Children with nephrotic syndrome may have growth retardation as a result of chronic steroid therapy. In most instances of NS, growth hormone levels are below normal. Corticosteroid cumulative doses have a negative impact on linear growth. | ||||
| Keywords | ||||
| Corticosteroid; Growth hormone; Nephrotic syndrome; Evaluation | ||||
|
Statistics Article View: 216 PDF Download: 490 |
||||
